Calcium Hydroxyapatite (Synthetic / Tribasic Calcium Phosphate)

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Synthetic calcium hydroxyapatite (tribasic calcium phosphate, Ca10(PO4)6(OH)2) is a lab-made version of the mineral found in bone — distinct from microcrystalline hydroxyapatite (MCHA, bovine bone-derived). Provides calcium + phosphorus in identical structure to bone mineral, but without the bovine-source organic matrix. It is usually cheaper than MCHA and suits vegetarians and vegans. One important limitation: every published trial behind hydroxyapatite's bone reputation used the bovine bone-derived forms (ossein-hydroxyapatite complex or microcrystalline hydroxyapatite), mostly in postmenopausal women. The synthetic form has not been tested for bone outcomes in people.

Studied Dose 1,000-1,200 mg elemental calcium per day from all sources, no more than about 500-600 mg at any one time; a general calcium target, not a dose tested for the synthetic form.
Active Compound Tribasic calcium phosphate / synthetic hydroxyapatite (Ca10(PO4)6(OH)2)

Benefits

Calcium + Phosphorus Combined

Synthetic calcium hydroxyapatite provides both calcium and phosphorus in the same crystalline structure as bone mineral. Most calcium supplements do not contain phosphorus, and bone needs both minerals. This remains a theoretical advantage. Trials have not shown that adding phosphorus beats calcium alone in people who already get enough phosphorus from food, which is most adults.

Vegetarian/Vegan Compatible

Unlike MCHA (bovine bone-derived), synthetic calcium hydroxyapatite is mineral-source only — appropriate for vegetarians, vegans, kosher/halal restrictions. No BSE/prion concerns from animal sourcing.

Slow Calcium Release

Hydroxyapatite dissolves more slowly than calcium carbonate or citrate, so the rise in blood calcium after a dose is smaller. That was measured in a randomized trial of the bovine-derived microcrystalline form in postmenopausal women (Bristow 2014), not the synthetic form, and it is not known whether a smaller spike changes any health outcome.

Cost-Effective vs MCHA

Synthetic calcium hydroxyapatite is generally cheaper than bovine-derived MCHA and supplies the same mineral. What it does not come with is MCHA's clinical trial record, so the lower price also means less evidence.

Food Industry Use

Tribasic calcium phosphate is widely used in foods as an anti-caking agent and a calcium fortifier, so it has a long history of food use. Being an approved food ingredient speaks to safety and handling, not to whether it helps bones.

Mechanism of action

1

Hydroxyapatite Crystal Structure

Identical mineral structure to human bone mineral: Ca10(PO4)6(OH)2. Slowly dissolves in stomach to release Ca²⁺ and phosphate ions for absorption.

2

Synthetic vs MCHA — Missing Organic Matrix

MCHA contains bovine bone matrix (collagen-derived peptides, growth factor remnants, trace elements). Synthetic calcium hydroxyapatite is mineral only — lacks the organic matrix components. Whether the matrix matters clinically is uncertain.

3

Phosphorus Co-Absorption

Provides phosphorus alongside calcium — supports bone matrix synthesis (which requires both). Most adults consume adequate phosphorus from diet, so additional phosphorus from supplements is rarely needed.

4

Slower Acute Absorption

Lower solubility means calcium is released more slowly than from carbonate or citrate, so blood calcium rises less after a dose. The idea that this reduces any cardiovascular risk from calcium supplements is speculation and has not been tested in a trial of this form.

Clinical trials

1
Absorption of Tribasic Calcium Phosphate (no specific trial cited)
PubMed

Scattered absorption comparisons of tribasic calcium phosphate against other calcium forms. No specific study is cited for this card, and none of the six references on this page tested the synthetic form.

Healthy adults / postmenopausal women.

Absorption appears broadly similar to calcium carbonate when taken with a meal, and there is far less head-to-head data than for carbonate or citrate. Delivering calcium is not the same as improving bone: no trial has tested the synthetic form for bone density or fractures.

2
Calcium + Phosphorus Combined for Bone Health — Limited
PubMed

Trials examining whether combined calcium + phosphorus supplementation provides additional bone benefit vs calcium alone.

Pooled across bone health RCTs.

No clear evidence that combined Ca+P supplementation outperforms calcium alone in adequate-phosphorus populations (most adults). Phosphorus deficiency is rare in typical Western diets. Theoretical advantage of hydroxyapatite forms not consistently demonstrated.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Constipation, as with other calcium supplements. Claims that it causes less constipation than calcium carbonate have not been tested for the synthetic form.
GI distress at high doses.
Larger pills due to lower elemental calcium content.
Same general calcium cautions as other forms.

Important Drug interactions

Same general calcium drug interactions — tetracyclines, quinolones, bisphosphonates, levothyroxine, iron; separate by 2-4 hours.
Phosphorus content — caution in CKD patients on phosphorus restriction.
Aluminum-containing drugs — separate dosing.
Thiazide diuretics — hypercalcemia risk.

Frequently asked questions about Calcium Hydroxyapatite (Synthetic / Tribasic Calcium Phosphate)

What is calcium hydroxyapatite?

Calcium hydroxyapatite is the form of calcium phosphate found naturally in bone. Supplements supply it as a calcium source that also provides phosphorus, and it is promoted for bone support. Two different materials are sold under the hydroxyapatite name: a bovine bone-derived form (ossein-hydroxyapatite complex or microcrystalline hydroxyapatite) and a synthetic mineral form (tribasic calcium phosphate). The published research used the bovine forms.

Is calcium hydroxyapatite good for bones?

It is marketed for bone density because it mirrors the mineral makeup of bone and includes phosphorus. Every supporting study used the bovine bone-derived forms: a meta-analysis and randomized comparisons of ossein-hydroxyapatite complex against calcium carbonate in postmenopausal women, one open-label trial in women already diagnosed with senile osteoporosis, and a four-year observational follow-up. None tested the synthetic form, and none of this means a supplement treats or prevents osteoporosis. What is well established is simpler: getting enough calcium from any well-absorbed form, along with vitamin D, supports normal bone.

How much calcium hydroxyapatite should I take?

Use it to fill the gap to a 1,000 to 1,200 mg daily calcium total, keeping single doses near 500 mg of elemental calcium. Check the label, and remember it also contributes phosphorus.

Is calcium hydroxyapatite safe?

It is generally well tolerated. The purity question applies mainly to the bovine bone-derived versions: bone-sourced calcium has a documented history of lead contamination and raises BSE/prion sourcing questions, so those products should come from suppliers that test every batch. The synthetic mineral form avoids both concerns, which is its clearest genuine advantage. As with all calcium, avoid excessive total intake and pair it with vitamin D.

What is Calcium Hydroxyapatite used for?

Calcium Hydroxyapatite is researched primarily for Bone Health. Synthetic calcium hydroxyapatite provides both calcium and phosphorus in the same crystalline structure as bone mineral. Most calcium supplements do not contain phosphorus, and bone needs both minerals. This remains a theoretical advantage.

What is the recommended dosage of Calcium Hydroxyapatite?

The clinically studied dose is 1,000-1,200 mg elemental calcium per day from all sources, no more than about 500-600 mg at any one time; a general calcium target, not a dose tested for the synthetic form. Always follow the product label and check with a healthcare provider for personal advice.

Is Calcium Hydroxyapatite safe, and does it have side effects?

For most healthy adults, Calcium Hydroxyapatite is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Constipation, as with other calcium supplements. Claims that it causes less constipation than calcium carbonate have not been tested for the synthetic form. It may also interact with some medications. Calcium Hydroxyapatite is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Calcium Hydroxyapatite interact with any medications?

Possible interactions include: Same general calcium drug interactions — tetracyclines, quinolones, bisphosphonates, levothyroxine, iron; separate by 2-4 hours. Phosphorus content — caution in CKD patients on phosphorus restriction. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Calcium Hydroxyapatite?

NutraSmarts rates the evidence for Calcium Hydroxyapatite as Limited (2 out of 5). It is backed by 2 clinical trials and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Castelo-Branco C, Ciria-Recasens M, Cancelo-Hidalgo MJ, Palacios S, Haya-Palazuelos J, Carbonell-Abelló J, Blanch-Rubió J, Martínez-Zapata MJ, Manasanch J, Pérez-Edo L. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause. 2009;16(5):984-91. doi: 10.1097/gme.0b013e3181a1824e.PubMedUsed to support: Meta-analysis concluding that ossein-hydroxyapatite complex, a bovine bone-derived material, is at least as effective as calcium carbonate for preventing bone loss in postmenopausal women. It pools earlier studies rather than adding new data, and it did not test the synthetic form described on this page.
  2. Castelo-Branco C, Cancelo Hidalgo MJ, Palacios S, Ciria-Recasens M, Fernández-Pareja A, Carbonell-Abella C, Manasanch J, Haya-Palazuelos J. Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric. 2020;23(3):252-258. doi: 10.1080/13697137.2019.1685488.PubMedUsed to support: Multicentre randomized trial comparing bovine bone-derived ossein-hydroxyapatite complex with calcium carbonate for preventing bone loss. It supports that material, not synthetic calcium hydroxyapatite.
  3. Bristow SM, Gamble GD, Stewart A, Horne L, House ME, Aati O, Mihov B, Horne AM, Reid IR. Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women. Br J Nutr. 2014;112(10):1611-20. doi: 10.1017/S0007114514002785.PubMedUsed to support: Randomized trial in postmenopausal women comparing bovine-derived microcrystalline hydroxyapatite with calcium citrate and calcium carbonate. It measured blood calcium and bone-turnover markers over three months, not bone density or fractures, and it did not test the synthetic form.
  4. Ciria-Recasens M, Blanch-Rubió J, Coll-Batet M, Del Pilar Lisbona-Pérez M, Díez-Perez A, Carbonell-Abelló J, Manasanch J, Pérez-Edo L. Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study. Clin Drug Investig. 2011;31(12):817-24. doi: 10.1007/BF03256920.PubMedUsed to support: Open-label randomized trial in women already diagnosed with senile osteoporosis, in which bovine-derived ossein-hydroxyapatite complex changed bone-metabolism markers compared with calcium carbonate. Open-label means everyone knew who got what, the participants were patients rather than healthy adults, and the synthetic form was not tested.
  5. Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, Riera Rubio VJ, Palazuelos JH, Dalmau JM. Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. Clin Drug Investig. 2007;27(4):227-32. doi: 10.2165/00044011-200727040-00001.PubMedUsed to support: Four-year observational follow-up of a cohort of postmenopausal women given bovine-derived ossein-hydroxyapatite complex. A cohort study can describe what happened over time but cannot show the supplement caused it, and it did not test the synthetic form.
  6. Castelo-Branco C, Dávila Guardia J. Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review. Climacteric. 2015;18(1):29-37. doi: 10.3109/13697137.2014.929107.PubMedUsed to support: Narrative review of bovine-derived ossein-hydroxyapatite complex for preventing bone loss. A review summarizes other researchers' data rather than adding new evidence, and its subject is the bone-derived material, not the synthetic one.